• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Abiomed touts latest Impella trial results

Abiomed touts latest Impella trial results

October 15, 2020 By Nancy Crotti

The Abiomed Impella CP heart pump [Image courtesy of National Institutes of Health]
Abiomed (NSDQ:ABMD) today announced interim results of a study that found high-risk patients had better outcomes after implantation with its Impella CP heart pump.

Data from the PROTECT III FDA post-approval study of Impella 2.5 and Impella CP in high-risk percutaneous coronary intervention (PCI) patients showed reduced rates of MACCE — a composite of death, stroke, myocardial infarction and repeat procedures.

PROTECT III builds on the PROTECT II randomized controlled trial (RCT) which found, when compared to intra-aortic balloon pump (IABP), Impella use led to a 29% reduction in MACCE at 90 days, the company said.

Patients selected for PROTECT III  would have qualified for PROTECT II but were older, sicker and more complex, with more comorbidities, more vessels treated and more rotational atherectomy, according to Abiomed. These “PII-like” patients in PROTECT III had improved 90-day MACCE rates, compared to PROTECT II patients (15% vs. 21.9%, p=0.035).

The PROTECT series of FDA clinical studies, which includes PROTECT I, the PROTECT II RCT and PROTECT III, is the largest-ever FDA study of hemodynamically supported high-risk PCI patients. The PROTECT III interim analysis included 1,143 patients undergoing elective, non-emergent PCI with Impella at 45 sites between March 2017 and September 2019.

The study also found PII-like patients in PROTECT III they had improved in-hospital safety with:

  • Significantly fewer bleeding complications (1.8% vs. 12.5%, p<0.001).
  • Similar low vascular complications (1.0% vs. 1.4%, p=0.659).
  • Similar low instances of stroke (0.40% vs. 0.46%, p=0.913).

“This data is an important continuation of knowledge in high-risk PCI. Looking back at PROTECT II data, we understood the safety and efficacy of Impella,” said lead investigator Dr. Jeffrey W. Moses, director of interventional cardiovascular therapeutics and professor of medicine at Columbia University Medical Center, in a news release. “But now, with PROTECT III showing fewer adverse events, we understand how to apply best practices and the result is better patient outcomes.”

Dr. William O’Neill, medical director of the Center for Structural Heart Disease at Henry Ford Hospital, is scheduled to present the results at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation, as a part of the “Best of Abstracts” session at 3:24 p.m. EDT today.

“This novel, contemporary data from PROTECT III clearly demonstrates how the evolution and adoption of Impella best practices can lead to an improvement in safety and MACCE and it provides important information as we prepare for the upcoming PROTECT IV Randomized Controlled Trial of Impella in high-risk PCI,” O’Neill said in the news release.

The PROTECT III post-approval study will inform best practice protocols for the upcoming prospective, two-arm PROTECT IV RCT, which will use and validate findings from the cVAD study, Impella Quality (IQ) Database and real-world data collected since the completion of the PROTECT II RCT. PROTECT IV will compare complete revascularization PCI with Impella to complete revascularization PCI without any planned hemodynamic support. The first patient is expected to enroll in 2021.

Filed Under: Cardiovascular, Clinical Trials, Featured, Food & Drug Administration (FDA), Implants Tagged With: Abiomed, FDA, TCT 2020

More recent news

  • Real-world data backs Route 92 reperfusion system
  • LivsMed unveils new surgical robot with telesurgery capabilities
  • JenaValve enrolls first patient in TAVR for AR study
  • HistoSonics expands insurance coverage for histotripsy treatment
  • Johnson & Johnson MedTech gets updated FDA nod for Varipulse PFA

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy